Yahoo Web Search

  1. While the 1990s and early 2000s were characterized by giant megadeals, heavyweight acquisitions in recent years - such as Teva's purchase of Allergan's generics division in 2015, Shire's ...

  2. Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people ...

  3. AbbVie: Fundamental Disconnect

    Seeking Alpha5 hours ago

    The performance of AbbVie (ABBV) shares through 2018 can be characterized as lackluster. A lot of pessimism is built into the share price relating to two failed clinical tests by Rova T and ...

  4. Rosenbloom, President and CEO of the Senior Care Pharmacy Coalition (SCPC), said the findings demonstrate the impact of generics on slower growth in drug spending between 2010-2014 and ...

  5. Coke vs. Pepsi is one of the most heated debates in foodie history. We tried these brands, plus six others, in a cola taste test to put this argument to bed.

  6. Novartis AG saw sales of one of its key drugs rebound last quarter, helping counter the impact of cheaper copycats on older products. Cosentyx’s sales increased 40 percent to $701 million in ...

  7. President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month.

  8. Swiss pharma giant Novartis AG NVS reported results for second-quarter 2018, wherein revenues beat estimate, driven by strong performance of Cosentyx and Entresto. However, earnings fell short ...

  9. What to Expect from Novartis’s Q2 2018 Earnings (Continued from Prior Part) Sandoz: Novartis’s generics segment Sandoz represents Novartis’s (NVS) generic products, including pharmaceuticals ...

  10. Its business is classified into the following three business segments: Innovative Medicines: prescription medicines Sandoz: generics Alcon: eye care

  1. 12345114 results